Close

23 abril, 2021

MIMIX™ Infectious Disease: Making Vaccines Radically More Effective and Accessible

The U.S. National Institute of Allergy & Infectious Diseases (NIAID) has awarded Vaxess Technologies up to $2.85M to develop & commercialize its Mimix vaccine delivery system.

Using intradermal microneedles for sustained delivery, the wearable unit is designed to mimic natural infection kinetics.

The first human clinical trials of the platform will test its effectiveness in delivering vaccines against seasonal influenza & SARS-CoV-2.

http://vaxess.com/mimix/mimix-infectious-disease/?fbclid=IwAR0yR5O_YyZeG1ekVZCwN3cMBv0ht80t31UP4smuNwmQxk959MBiMObGLIk


Créditos: Comité científico Covid

Deja un comentario

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *